drug monitoring
Recently Published Documents


TOTAL DOCUMENTS

4918
(FIVE YEARS 1269)

H-INDEX

89
(FIVE YEARS 13)

2022 ◽  
Vol 7 (2) ◽  
pp. 171-185
Author(s):  
Konstantinos Papamichael ◽  
Waqqas Afif ◽  
David Drobne ◽  
Marla C Dubinsky ◽  
Marc Ferrante ◽  
...  

Author(s):  
Eduard Schmulenson ◽  
Nigina Zimmermann ◽  
Gerd Mikus ◽  
Markus Joerger ◽  
Ulrich Jaehde

2022 ◽  
pp. 002214652110672
Author(s):  
Mike Vuolo ◽  
Laura C. Frizzell ◽  
Brian C. Kelly

Policy mechanisms shaping population health take numerous forms, from behavioral prohibitions to mandates for action to surveillance. Rising drug overdoses undermined the state’s ability to promote population-level health. Using the case of prescription drug monitoring programs (PDMPs), we contend that PDMP implementation highlights state biopower operating via mechanisms of surveillance, whereby prescribers, pharmacists, and patients perceive agency despite choices being constrained. We consider whether such surveillance mechanisms are sufficient or if prescriber/dispenser access or requirements for use are necessary for population health impact. We test whether PDMPs reduced overdose mortality while considering that surveillance may require time to reach effectiveness. PDMPs reduced opioid overdose mortality 2 years postimplementation and sustained effects, with similar effects for prescription opioids, benzodiazepines, and psychostimulants. Access or mandates for action do not reduce mortality beyond surveillance. Overall, PDMP effects on overdose mortality are likely due to self-regulation under surveillance rather than mandated action.


2022 ◽  
pp. ejhpharm-2021-003036
Author(s):  
Stefan Günther ◽  
Andreas Reimer ◽  
Horst Vogl ◽  
Stephan Spenke ◽  
Hanns-Christian Dinges ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document